New Patient Reported Outcomes (PRO) data presented by today at the European Association for the Study of Diabetes (EASD) congress in Stockholm challenge the widespread perception that patients prefer oral to injected glucose-lowering therapies.
Results from the 26-week, open-label study show that patients taking injectable Victoza (liraglutide 1.8 mg) reported significantly higher overall treatment satisfaction after 26 weeks than those receiving oral Januvia (sitagliptin). Notably, patients rated Victoza 1.8 mg as convenient as Januvia and were more likely both to continue treatment themselves, and to recommend Victoza to another patient.
Additional data from the study demonstrated that both HbA1c reduction and weight loss were significantly greater with Victoza than Januvia when added to a stable dose of metformin.
Additional data from the study demonstrated that both HbA1c reduction and weight loss were significantly greater with Victoza than Januvia when added to a stable dose of metformin.
For the full Novo Nordisk press release click here.
